Artificial intelligence and health: in Italy, pharmaceutical companies still need to improve online transparency
Artificial intelligence is rapidly changing the way citizens search for health information online. More and more people are using advanced digital tools to get quick answers to medical questions, but the European pharmaceutical sector seems to be struggling to keep pace with this technological evolution, especially regarding data management and the clarity of information.
A recent analysis conducted on the pharmaceutical sector has highlighted a critical situation in Italy. Despite the growing prevalence of chatbots and virtual assistants based on artificial intelligence, companies in the sector have not yet adopted clear rules to protect users. Currently, only 4.2% of Italian pharmaceutical websites publish explicit policies on the use of artificial intelligence.
This lack of transparency creates several concerns for patients. Without precise guidelines, it is difficult for users to understand how their queries are processed or how reliable the automatically generated answers are. Digital governance, or the set of rules that manage the use of technology, currently appears much slower than the development of new IT tools.
Experts emphasize that, in a sensitive field like healthcare, trust between company and patient is fundamental. For this reason, it is necessary for Italian pharmaceutical companies to begin implementing more rigorous security protocols, clearly informing users about how technology is used within their digital platforms.
In conclusion, although innovation offers great opportunities to improve access to health information, the sector must now focus on responsibility. The goal for the near future will be to bridge the gap between the use of artificial intelligence and the creation of transparent regulation, thereby ensuring greater protection for all Italian citizens.